Polypid Ltd (PYPD) Stock Price, Quote & News

Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, which is in...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 7 4719 5700

Website: www.polypid.com

Address:

18 Hasivim Street, Petah Tikva, Israel

Project_Profit Sep. 3 at 2:48 PM

$PYPD Under the radar until it's on the radar $XBI

0 · Reply

WallStWireAds Sep. 3 at 12:32 PM

$PYPD https://caplynx.io/1qOjDVd

0 · Reply

WallStWireAds Sep. 2 at 12:31 PM

$PYPD https://caplynx.io/DvSusVo

0 · Reply

haily_haily Sep. 2 at 10:35 AM

$PYPD what the fuck happened here

1 · Reply

Finanz Aug. 29 at 9:40 PM

$PYPD https://www.youtube.com/watch?v=uF8VxpyLJX0

0 · Reply

alphawolftrading Aug. 29 at 8:22 PM

$PYPD https://youtu.be/uF8VxpyLJX0?si=dhReM0XRbXcbgoDO

1 · Reply

WallStWireAds Aug. 20 at 7:35 AM

$PYPD https://alphacatalyst.beehiiv.com/p/the-race-for-oral-glp-1-eli-lilly-s-diassppointing-trial-results-turn-the-spotlight-to-polypid-s-inn

1 · Reply

WallStWireAds Aug. 18 at 1:18 PM

$PYPD https://www.tipranks.com/news/company-announcements/polypid-reports-positive-phase-3-results-and-strengthens-leadership

0 · Reply

BenGang Aug. 15 at 6:50 PM

$PYPD

0 · Reply

CARTE_BLANCHE_DEVEREAUX Aug. 15 at 5:05 PM

$PYPD 20cm is good enough for this to 10x easily. A foot in the door to 7 cm... and the wheelbarrow that you're carrying your balls around in... gets a couple brothers to carry your cash out. Building on a (already big) position here, taking it slow cuz big orders push the price too much. And I think we have a couple months to accrue. 3xB. 1xS. (Ra: 3.28-3.86)

3 · Reply

PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference

Aug 13, 2025, 4:52 PM EDT - 21 days ago

PolyPid Ltd. (PYPD) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 7:30 AM EDT - 21 days ago

PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 12, 2025, 8:00 AM EDT - 22 days ago

PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

Jul 30, 2025, 8:00 AM EDT - 5 weeks ago

PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025

Jul 15, 2025, 8:00 AM EDT - 7 weeks ago

PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market

Jun 16, 2025, 7:20 PM EDT - 2 months ago

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

Jun 11, 2025, 9:42 AM EDT - 3 months ago

PESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

Jun 11, 2025, 9:40 AM EDT - 3 months ago

PESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

Jun 9, 2025, 8:54 AM EDT - 3 months ago

BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript

Jun 9, 2025, 7:30 AM EDT - 3 months ago

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

Jun 6, 2025, 4:05 PM EDT - 3 months ago

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

May 30, 2025, 10:12 AM EDT - 3 months ago

PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data Readout

May 20, 2025, 7:00 AM EDT - 3 months ago

PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

May 14, 2025, 1:24 PM EDT - 4 months ago

PolyPid Ltd. (PYPD) Q1 2025 Earnings Call Transcript

May 14, 2025, 7:00 AM EDT - 4 months ago

PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results

Apr 29, 2025, 7:00 AM EDT - 4 months ago

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025

Apr 22, 2025, 7:00 AM EDT - 4 months ago

PolyPid to Participate in The Citizens Life Sciences Conference

Mar 11, 2025, 7:00 AM EDT - 6 months ago

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Mar 3, 2025, 7:00 AM EST - 6 months ago

PolyPid to Participate in the 37th Annual ROTH Conference

Feb 12, 2025, 10:44 AM EST - 7 months ago

PolyPid Ltd. (PYPD) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 7:00 AM EST - 7 months ago

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Jan 30, 2025, 7:00 AM EST - 7 months ago

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 29, 2025, 7:00 AM EST - 7 months ago

PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025

Dec 26, 2024, 10:31 AM EST - 8 months ago

Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday

KMPR ACVA AVXL

Dec 23, 2024, 7:22 PM EST - 9 months ago

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million

Dec 11, 2024, 7:00 AM EST - 9 months ago

PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy

Nov 29, 2024, 1:05 PM EST - 9 months ago

PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

Nov 13, 2024, 2:06 PM EST - 10 months ago

PolyPid Ltd. (PYPD) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 7:00 AM EST - 10 months ago

PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference

Oct 30, 2024, 8:00 AM EDT - 11 months ago

PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024

Oct 21, 2024, 7:00 AM EDT - 11 months ago

PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

Oct 1, 2024, 7:00 AM EDT - 1 year ago

PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Sep 3, 2024, 7:00 AM EDT - 1 year ago

PolyPid to Participate in Three Upcoming Fall Investor Conferences

Aug 14, 2024, 1:25 PM EDT - 1 year ago

PolyPid Ltd (PYPD) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 8:31 PM EDT - 1 year ago

PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds

Jul 31, 2024, 7:00 AM EDT - 1 year ago

PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024

Jun 10, 2024, 7:00 AM EDT - 1 year ago

PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company's Ongoing D-PLEX₁₀₀ Phase 3 Trial

May 9, 2024, 10:38 PM EDT - 1 year ago

PolyPid Ltd (PYPD) Q1 2024 Earnings Call Transcript

May 8, 2024, 7:00 AM EDT - 1 year ago

PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 1, 2024, 7:00 AM EDT - 1 year ago

PolyPid to Participate in Citizens JMP Life Sciences Conference

Apr 30, 2024, 7:00 AM EDT - 1 year ago

PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Apr 24, 2024, 7:00 AM EDT - 1 year ago

PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024

Feb 28, 2024, 7:00 AM EST - 1 year ago

PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference

Feb 14, 2024, 11:13 AM EST - 1 year ago

PolyPid Ltd (PYPD) Q4 2023 Earnings Call Transcript

Feb 14, 2024, 7:00 AM EST - 1 year ago

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 12, 2024, 7:00 AM EST - 1 year ago

PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial

Jan 31, 2024, 7:00 AM EST - 1 year ago

PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024

Jan 4, 2024, 4:32 PM EST - 1 year ago

PolyPid Announces Private Placement for $16 Million in Gross Proceeds

Nov 12, 2023, 1:08 AM EST - 1 year ago

PolyPid Ltd. (PYPD) Q3 2023 Earnings Call Transcript

Project_Profit Sep. 3 at 2:48 PM

$PYPD Under the radar until it's on the radar $XBI

0 · Reply

WallStWireAds Sep. 3 at 12:32 PM

$PYPD https://caplynx.io/1qOjDVd

0 · Reply

WallStWireAds Sep. 2 at 12:31 PM

$PYPD https://caplynx.io/DvSusVo

0 · Reply

haily_haily Sep. 2 at 10:35 AM

$PYPD what the fuck happened here

1 · Reply

Finanz Aug. 29 at 9:40 PM

$PYPD https://www.youtube.com/watch?v=uF8VxpyLJX0

0 · Reply

alphawolftrading Aug. 29 at 8:22 PM

$PYPD https://youtu.be/uF8VxpyLJX0?si=dhReM0XRbXcbgoDO

1 · Reply

WallStWireAds Aug. 20 at 7:35 AM

$PYPD https://alphacatalyst.beehiiv.com/p/the-race-for-oral-glp-1-eli-lilly-s-diassppointing-trial-results-turn-the-spotlight-to-polypid-s-inn

1 · Reply

WallStWireAds Aug. 18 at 1:18 PM

$PYPD https://www.tipranks.com/news/company-announcements/polypid-reports-positive-phase-3-results-and-strengthens-leadership

0 · Reply

BenGang Aug. 15 at 6:50 PM

$PYPD

0 · Reply

CARTE_BLANCHE_DEVEREAUX Aug. 15 at 5:05 PM

3 · Reply

PaulWalter Aug. 15 at 7:24 AM

$PYPD this just has so much going for it. Great late stage products and plenty of cash. Cant get any love. ESG / Israel thing? They need US partner asap.

0 · Reply

JarvisFlow Aug. 14 at 5:44 PM

Craig-Hallum updates rating for PolyPid ( $PYPD ) to Buy, target set at 15 → 13.

0 · Reply

PaulWalter Aug. 14 at 5:16 PM

$PYPD

0 · Reply

YoloAlfred Aug. 14 at 2:01 PM

$PYPD 🤔🤔🤔🤔🤔

0 · Reply

WallStWireAds Aug. 13 at 11:37 AM

$PYPD https://www.globenewswire.com/news-release/2025/08/13/3132467/0/en/PolyPid-Provides-Corporate-Update-and-Reports-Second-Quarter-2025-Financial-Results.html

0 · Reply

WallStWireAds Aug. 13 at 7:45 AM

$PYPD https://www.globenewswire.com/news-release/2025/08/12/3131617/0/en/PolyPid-Appoints-Dr-Nurit-Tweezer-Zaks-as-Chief-Medical-Officer.html

0 · Reply

WallStWireAds Aug. 11 at 2:58 PM

$PYPD https://www.clinicalleader.com/doc/running-global-clinical-trials-polypid-shares-operational-and-regulatory-insights-0001

0 · Reply

PaulWalter Aug. 6 at 4:26 PM

$PYPD Looks like someone gave up. cant blame them

1 · Reply

PaulWalter Aug. 1 at 8:45 PM

$PYPD wen lambo?

0 · Reply

pandodark Jul. 28 at 6:24 PM

$PYPD Can’t underestimate how big of a product this will be. Probably a 20 bagger if you’re patient.

0 · Reply

CARTE_BLANCHE_DEVEREAUX Jul. 25 at 2:19 PM

$ATHE OH MY BABY BOY IS GROWING UP SO FAST!!! $CING is also about to fly. $SLS $PYPD or $ANRO ... what will follow?

0 · Reply

CARTE_BLANCHE_DEVEREAUX Jul. 18 at 7:34 PM

$ATHE $OUST $SLS $PYPD $ANRO Wishing everybody a great weekend... And a reminder:

3 · Reply

Market Cap	54.21M
Revenue (ttm)	0.00
Net Income (ttm)	-29.02M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.32

Volume	175,400
Avg Vol	102,206
Day's Range	N/A - N/A
Shares Out	15.90M
Stochastic %K	38%
Beta	1.48
Analysts	Strong Sell
Price Target	$12.50